Health care stocks were flat to lower pre-bell Monday, with The Health Care Select Sector SPDR Fund (XLV) unchanged and the iShares Biotechnology ETF (IBB) down 0.4%.
Corcept Therapeutics (CORT) shares were up over 93% after the company said its phase 3 trial of relacorilant plus nab-paclitaxel to treat a type of ovarian cancer met its primary goal.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.